Share Price, page-12112

yeah, just the initial adjustment needed for a new drug coming onto the market. The fact acadia revised their figures and gave a narrower range shows their increased confidence in hitting those targets. A lot of upside for daybue, especially with row starting to come online in the not too distant future.

I do think the market is too short term in their thinking and focus on daybue revenue, much bigger and better things to come. This is where I think Jon has failed, he has failed to sell the growth story of neu to the market and the shareprice has suffered. He has an opportunity to get it right with the upcoming post fda update.